Connect with us


Javid expected to back scrapping of locator forms for England arrivals | Transport policy



Sajid Javid is expected to back the scrapping of passenger locator forms for all international arrivals in England before Easter, the Guardian has learned.

The health secretary has acquiesced to pressure from the transport secretary, Grant Shapps, and Tory MPs concerned about the requirement, which has remained despite domestic restrictions having been rolled back.

Currently, all travellers – apart from those arriving on internal flights or journeys that began in Ireland, the Channel Islands and Isle of Man – must complete a passenger locator form before beginning their journey to the UK.

The form became a requirement when border controls were much stricter and allowed officials to ensure people complied with quarantine rules.

It has been simplified over time, but the Ryanair boss, Michael O’Leary, complained that scrapping the forms was long overdue. He called them “completely irrelevant” because “nobody collects them, nobody checks them or follows up on them”.

Javid, Shapps and other senior ministers are expected to sign off on the decision to scrap the forms at a meeting of the Covid operations committee next Monday. A government source said the “expectation is to remove all remaining Covid border measures” and speculated that the requirement for unvaccinated travellers to get tested on arrival could also be dropped.

After the public row over Novak Djokovic’s vaccination status and culminating in his removal from Australia, the source noted it could mean the tennis player would be able to attend Wimbledon this summer.

Others doubted that Javid would back the move to end the testing requirement, particularly given the wider Covid backdrop, with cases and hospitalisations both rising.

Prof Denis Kinane, an immunologist and founder of Cignpost Diagnostics, said it was “very concerning” that the testing rule could be changed. He added: “Any move to scrap testing for unvaccinated travellers will hinder our ability to detect new variants and to analyse the mutation of the virus.”

Changes to the travel rules could come into effect in time for the Easter holidays next month, to allow families to travel abroad and return more easily.

Huw Merriman, the Conservative MP who chairs the Commons transport select committee, said he and colleagues were pushing for the forms to be dropped, adding that the Department for Transport “cannot see the point of it”.

He told the Business Travel Association’s spring conference earlier this month: “We don’t need restrictions domestically so why the heck do we need to be asking all these questions of people when they come back into the country?”

He added: “It’s our job to put it to the prime minister and then ultimately to try and get it [the form] dropped by Easter, which I’m pretty confident we’ll do. We have to constantly chip away. It’s slower than I’d like – but we do get there.”

The travel industry has been one of the heaviest hit by Covid restrictions. While its supporters concede the passenger locator form is a relatively small measure they do not think puts many people off travelling, they are keen to clear up the disparity between some rules existing for international arrivals and the lack of any domestic restrictions.

Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published.


Solar storms may cause up to 5500 heart-related deaths in a given year



In an approximate 11-year cycle, the sun blasts out charged particles and magnetised plasma that can distort Earth’s magnetic field, which may disrupt our body clock and ultimately affect our heart


17 June 2022

A solar storm

Jurik Peter/Shutterstock

Solar storms that disrupt Earth’s magnetic field may cause up to 5500 heart-related deaths in the US in a given year.

The sun goes through cycles of high and low activity that repeat approximately every 11 years. During periods of high activity, it blasts out charged particles and magnetised plasma that can distort Earth’s magnetic field.

These so-called solar storms can cause glitches in our power grids and bring down Earth-orbiting satellites. A handful of studies have also hinted that they increase the risk of …

Source link

Continue Reading


UK Covid infection rate rising, with more than a million cases in England | Coronavirus



Coronavirus infections are rising in the UK, figures have revealed, with experts noting the increase is probably down to the more transmissible BA.4 and BA.5 Omicron variants.

The figures from the Office for National Statistics (ONS), based on swabs collected from randomly selected households, reveal that in the week ending 11 June an estimated one in 50 people in the community in England are thought to have had Covid – around 1.13 million people.

The figure is even higher, at one in 45, in both Wales and Northern Ireland, while it was highest in Scotland where, in the week ending 10 June, one in 30 people are thought to have been infected.

While the figures remain below the peak levels of infection seen earlier this year, when around one in 13 people in England had Covid, the findings are a rise on the previous week where one in 70 people in England were thought to be infected. Furthermore, the data reveals increases in all regions of England, except the north-east, and across all age groups.

Experts say that a key factor in the increase is probably the rise of the Covid variants of concern BA.4 and BA.5.

“Infections have increased across all four UK nations, driven by rising numbers of people infected with the BA.4 and BA.5 Omicron variants,” said Kara Steel, senior statistician for the Covid-19 Infection Survey.

While Steel said it remained too early to say if this was the start of another wave, others have warned it may already have begun, with increased mixing and travelling among other factors fuelling a rise in cases.

Among concerns scientists have raised are that BA.4, BA.5 and another variant on the rise, BA.2.12.1, replicate more efficiently in human lung cells than BA.2.

Prof Azra Ghani, an epidemiologist at Imperial College London, said the latest figures were not surprising, and might rise further.

“This increase in infection prevalence is likely due to the growth of the BA.4 and BA.5 Omicron subvariants, which as we have seen elsewhere in Europe, appear to be able to escape immunity generated from previous Omicron subvariants,” she said.

“It is therefore possible that we will continue to see some growth in infection prevalence in the coming weeks and consequently an increase in hospitalisations, although these subvariants do not currently appear to result in any significantly changed severity profile. This does however serve as a reminder that the Covid-19 pandemic is not over.”

Source link

Continue Reading


NHS to offer women in England drug that cuts recurrence of breast cancer | Breast cancer



Thousands of women in England with breast cancer are to benefit from a new pill on the NHS which reduces the risk of the disease coming back.

The National Institute for Health and Care Excellence (Nice) has given the green light to abemaciclib, which cuts the chance of breast cancer returning after a patient has had surgery to remove a tumour.

Trials showed that patients who had the drug with hormone therapy had a more than 30% improved chance of their cancer not coming back after surgery, compared with hormone therapy alone.

“It’s fantastic thousands of women with this type of primary breast cancer will now have an additional treatment option available on the NHS to help further reduce the risk of the disease coming back,” said Delyth Morgan, the chief executive of charity Breast Cancer Now.

“The fear of breast cancer returning or spreading to other parts of their body and becoming incurable can cause considerable anxiety for so many women and their loved ones.

“New effective treatments such as abemaciclib, which can offer more women the chance to further reduce the risk of the disease recurring, are therefore extremely welcome and this is an important step change in the drug options available for this group of patients.”

The twice-a-day pill is suitable for women with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence who have had surgery. About 4,000 women will benefit initially, Nice said.

Helen Knight, the interim director of medicines evaluation at Nice, said the draft recommendation came less than a month after abemaciclib received its licence.

“The fact that we have been able to produce draft recommendations so quickly is testament to the success of our ambition to support patient access to clinically and cost effective treatments as early as possible,” said Knight. “Until now there have been no targeted treatments for people with this type of breast cancer.

“Abemaciclib with hormone therapy represents a significant improvement in how it is treated because being able to have a targeted treatment earlier after surgery will increase the chance of curing the disease and reduce the likelihood of developing incurable advanced disease.”

Abemaciclib works by targeting and inhibiting proteins in cancer cells which allow the cancer to divide and grow. It normally costs £2,950 for a packet of 56 150mg-tablets, but the manufacturer, Eli Lilly, has agreed an undisclosed discounted price for NHS England.

“Thanks in part to this latest deal struck by NHS England, NHS patients will be able to access another new targeted drug for a common and aggressive form of breast cancer,” said Prof Peter Johnson, the cancer director of NHS England.

“Abemaciclib, when used alongside a hormone therapy, offers a new, doubly targeted, treatment option, helping to increase the chances of beating the cancer for good, as well as meeting the NHS’s commitment to delivering improved cancer care under our long-term plan.”

Source link

Continue Reading